Trial Profile

A Phase 1b/2 study of evaluating stenoparib in combination with dovitinib second-line or later treatment in the patients with metastatic ovarian cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2023 According to an Allarity Therapeutics media release, the validation of DRP companion diagnostics in advance of an anticipated DRP-guided Phase 2 trial of the dovitinib and stenoparib combination in second line or later metastatic ovarian cancer, targeted for H2 2024.
07 Nov 2022 According to an Allarity Therapeutics media release, company has decided to delay the enrollment of patients in its previously announced anticipated, this trial until it has raised additional capital.
07 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com